432 related articles for article (PubMed ID: 31659567)
21. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of [
Vermeulen K; Naus E; Ahamed M; Attili B; Siemons M; Luyten K; Celen S; Schymkowitz J; Rousseau F; Bormans G
Theranostics; 2019; 9(2):554-572. PubMed ID: 30809293
[TBL] [Abstract][Full Text] [Related]
23. Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.
Li L; Yang M; Li C; Liu Y
Naunyn Schmiedebergs Arch Pharmacol; 2021 Nov; 394(11):2223-2232. PubMed ID: 34406420
[TBL] [Abstract][Full Text] [Related]
24. The Hsp90 chaperone machinery: from structure to drug development.
Hahn JS
BMB Rep; 2009 Oct; 42(10):623-30. PubMed ID: 19874705
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kα) against cutaneous melanoma.
Qin F; Wang Y; Jiang X; Wang Y; Zhang N; Wen X; Wang L; Jiang Q; He G
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):909-926. PubMed ID: 30957641
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
27. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
28. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
29. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
30. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
31. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma.
Barbagallo I; Parenti R; Zappalà A; Vanella L; Tibullo D; Pepe F; Onni T; Li Volti G
Acta Histochem; 2015 Oct; 117(8):705-11. PubMed ID: 26493719
[TBL] [Abstract][Full Text] [Related]
32. Ultrasound-targeted microbubble destruction combined with dual targeting of HSP72 and HSC70 inhibits HSP90 function and induces extensive tumor-specific apoptosis.
Wang H; Song Y; Hao D; Bai M; Jin L; Gu J; Su Y; Liu L; Jia C; Du L
Int J Oncol; 2014 Jul; 45(1):157-64. PubMed ID: 24736948
[TBL] [Abstract][Full Text] [Related]
33. Binding of natural and synthetic inhibitors to human heat shock protein 90 and their clinical application.
Petrikaitė V; Matulis D
Medicina (Kaunas); 2011; 47(8):413-20. PubMed ID: 22123555
[TBL] [Abstract][Full Text] [Related]
34. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs.
Phillips JJ; Yao ZP; Zhang W; McLaughlin S; Laue ED; Robinson CV; Jackson SE
J Mol Biol; 2007 Oct; 372(5):1189-203. PubMed ID: 17764690
[TBL] [Abstract][Full Text] [Related]
35. Heat shock protein 90: the cancer chaperone.
Neckers L
J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
[TBL] [Abstract][Full Text] [Related]
36. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
[TBL] [Abstract][Full Text] [Related]
37. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy.
Hwang M; Moretti L; Lu B
Curr Med Chem; 2009; 16(24):3081-92. PubMed ID: 19689285
[TBL] [Abstract][Full Text] [Related]
38. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV; Workman P
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
[TBL] [Abstract][Full Text] [Related]
39. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
